Patent · US Active

Pyrrolidine derivatives as PPAR agonists

US10526320B2 · kind B2 · utility

2Cited by

0References

20Claims

0Family size

Assignee

GUANGDONG RAYNOVENT BIOTECH CO., LTD. · CN

Inventors

Zhiliang Yuan · Shanghai, CN
Chaofeng Long · Tangxia, CN
Zhigan Jiang · Shanghai, CN
Xiaoxin Chen · Cupertino, US
Haiying He · Shanghai, CN
Xing Liu · Hefei, CN
Xiao Zhang · Shanghai, CN
Zhiqiang Liu · Kyoto, JP
Yan Wang · San Diego, US
Leilei Gao · Shanghai, CN
Zhen Gong · Shanghai, CN
Jian Li · Shanghai, CN
Shuhui CHEN · Shanghai, CN

Key dates

Filing date	Jul 12, 2017
Grant date	Jan 7, 2020
Priority date	—
Expiry date	Jul 12, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D403/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.